$TRDA

$4.41 -$0.34 (7.16%) Close

$TRDA Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Company Executives

$TRDA Management Team

Dr. Kush Parmar

Independent Chairman of the Board

Age 44

Compensation $273.4K USD

Sex Male

Mr. Nathan Dowden

President

Chief Operating Officer

Age 55

Compensation $2.461M USD

Sex Male

Mr. Dipal Doshi

Chief Executive Officer

Director

Age 49

Compensation $3.892M USD

Sex Male

Mr. Kory Wentworth

Chief Financial Officer

Treasurer

Age 46

Compensation -

Sex Male

Dr. Natarajan Sethuraman

President of Research and Development

Age 63

Compensation $1.963M USD

Sex Male

Name / Title	Age	Compensation	Sex
Dr. Kush Parmar Independent Chairman of the Board	44	$273.4K USD	Male
Mr. Nathan Dowden President Chief Operating Officer	55	$2.461M USD	Male
Mr. Dipal Doshi Chief Executive Officer Director	49	$3.892M USD	Male
Mr. Kory Wentworth Chief Financial Officer Treasurer	46	-	Male
Dr. Natarajan Sethuraman President of Research and Development	63	$1.963M USD	Male

Board of Directors

From the proxy statement filed Apr 24, 2026

Directors

serving now

Independent

5 of 7

stated in the proxy

Average tenure

5.3 years

from year joined

CEO also chairs the board

Kush M. Parmar, M.D., Ph.D.

Director	Age	On board	Independent	Committees	Other public boards	2025 pay
Dipal Doshi CEO	50	2017 9 years	Not independent	None stated	Azenta, Inc.	Paid as CEO
Kush M. Parmar, M.D., Ph.D. Board chair	45	2016 10 years	Independent	Compensation Committee · Chair	None stated	Not stated
Mary Thistle	66	2021 5 years	Independent	Audit Committee · Chair	Atkis Oncology, Inc.	$167,427
Peter S. Kim, Ph.D.	67	2020 6 years	Not independent	None stated	None stated	Not stated
Bernhardt Zeiher, M.D.	62	2023 3 years	Independent	Compensation Committee	Amylyx Pharmaceuticals, Inc.	$150,680
Gina Chapman	58	2023 3 years	Independent	Audit Committee	None stated	$157,553
Maha Radhakrishnan, M.D.	56	2025 1 year	Independent	Audit Committee	Candel Therapeutics, Inc.	$230,927

Each director opens the passage of the proxy that names them. "Not stated" means the proxy does not say; it never means "no". Pay is the proxy's Director Compensation table; the CEO is paid as an executive.

No related-party transactions disclosed

The proxy filed Apr 24, 2026 describes a review policy but reports no transactions.

Read the policy in the proxy

Comments

Company Executives

$TRDA Management Team

Dr. Kush Parmar

Mr. Nathan Dowden

Mr. Dipal Doshi

Mr. Kory Wentworth

Dr. Natarajan Sethuraman

Board of Directors

Related-party transactions

No related-party transactions disclosed